BTIG initiated coverage of Oruka Therapeutics (ORKA) with a Buy rating and $44 price target The firm, which expects Oruka’s ORKA-001 and ORKA-002 monoclonal antibodies to thrive as monotherapies and also potentially in combination, sees “compelling reasons to believe” that ORKA-001 and ORKA-021 could eventually be confirmed with differentiated efficacy in the indications of psoriasis and psoriatic arthritis.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ORKA:
- Buy Rating for Oruka Therapeutics: Promising Pipeline and Strong Financial Position
- Oruka Therapeutics: Strong Financial Position and Promising Clinical Developments Support Buy Rating
- Oruka Therapeutics reports Q1 EPS (40c), consensus (47c)
- Oruka Therapeutics’ ORKA-001: Promising Developments and Buy Rating Justification